Rosen Law Firm has announced a securities class action lawsuit for purchasers of Ardelyx, Inc. common stock between January 13, 2025, and August 6, 2026, inclusive. The lawsuit, which has already been filed, alleges that Ardelyx defendants issued overly positive statements while concealing or misstating commercial performance and growth prospects for XPHOZAH and IBSRELA. The complaint focuses on payer-related access and reimbursement barriers, including stricter prior authorization and step edit requirements that allegedly slowed new-patient starts and delayed prescription fulfillment. Investors who want to seek lead-plaintiff status must move the Court by November 16, 2026. Potential class members may obtain information from Rosen Law Firm through its website, by contacting Phillip Kim, Esq., or by email. No class has been certified, and investors are not represented by counsel unless they retain one before certification. They may also remain absent class members without taking action, and eligibility for any potential future recovery does not depend on serving as lead plaintiff.